149 related articles for article (PubMed ID: 19818738)
1. Interleukin-2 induces the activities of DNA topoisomerase I and DNA topoisomerase II in HuT 78 cells.
Pham MH; Kondapalli N; Reckord CL; Foglesong PD
Biochem Biophys Res Commun; 2009 Dec; 390(3):577-80. PubMed ID: 19818738
[TBL] [Abstract][Full Text] [Related]
2. The activity of topoisomerases is related to the grade and stage in human renal cell carcinoma.
Shuin T; Sano K
Anticancer Res; 1994; 14(6B):2621-6. PubMed ID: 7872691
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
[TBL] [Abstract][Full Text] [Related]
4. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
Staley BE; Samowitz WS; Bronstein IB; Holden JA
Mod Pathol; 1999 Apr; 12(4):356-61. PubMed ID: 10229499
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.
Heck MM; Hittelman WN; Earnshaw WC
Proc Natl Acad Sci U S A; 1988 Feb; 85(4):1086-90. PubMed ID: 2829215
[TBL] [Abstract][Full Text] [Related]
6. Differential increase in topoisomerase II in simian virus 40-infected cells.
Rainwater R; Mann K
J Virol; 1990 Feb; 64(2):918-21. PubMed ID: 2153253
[TBL] [Abstract][Full Text] [Related]
7. Higher expression of topoisomerase II in lung cancers than normal lung tissues: different expression pattern from topoisomerase I.
Hasegawa T; Isobe K; Nakashima I; Shimokata K
Biochem Biophys Res Commun; 1993 Aug; 195(1):409-14. PubMed ID: 8395833
[TBL] [Abstract][Full Text] [Related]
8. Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions.
Zini N; Santi S; Ognibene A; Bavelloni A; Neri LM; Valmori A; Mariani E; Negri C; Astaldi-Ricotti GC; Maraldi NM
Exp Cell Res; 1994 Feb; 210(2):336-48. PubMed ID: 8299728
[TBL] [Abstract][Full Text] [Related]
9. Induction of alkylator (melphalan) resistance in HL60 cells is accompanied by increased levels of topoisomerase II expression and function.
Pu QQ; Bezwoda WR
Mol Pharmacol; 1999 Jul; 56(1):147-53. PubMed ID: 10385695
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
Utsugi T; Mattern MR; Mirabelli CK; Hanna N
Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
[TBL] [Abstract][Full Text] [Related]
11. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors.
Pommier Y; Kerrigan D; Schwartz RE; Swack JA; McCurdy A
Cancer Res; 1986 Jun; 46(6):3075-81. PubMed ID: 3009009
[TBL] [Abstract][Full Text] [Related]
12. Studies on DNA topoisomerases I and II in herpes simplex virus type 2-infected cells.
Bapat AR; Han FS; Liu ZC; Zhou BS; Cheng YC
J Gen Virol; 1987 Aug; 68 ( Pt 8)():2231-7. PubMed ID: 3039049
[TBL] [Abstract][Full Text] [Related]
13. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.
Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M
Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282
[TBL] [Abstract][Full Text] [Related]
14. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Cornarotti M; Capranico G; Bohm S; Oriana S; Spatti GB; Mariani L; Ballabio G; Zunino F
Int J Cancer; 1996 Aug; 67(4):479-84. PubMed ID: 8759604
[TBL] [Abstract][Full Text] [Related]
15. Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects.
Boege F
Eur J Clin Chem Clin Biochem; 1996 Nov; 34(11):873-88. PubMed ID: 8960461
[TBL] [Abstract][Full Text] [Related]
16. Etoposide-induced DNA cleavage in human leukemia cells.
Edwards CM; Glisson BS; King CK; Smallwood-Kentro S; Ross WE
Cancer Chemother Pharmacol; 1987; 20(2):162-8. PubMed ID: 2822274
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas.
Hafian H; Venteo L; Sukhanova A; Nabiev I; Lefevre B; Pluot M
Hum Pathol; 2004 Jun; 35(6):745-51. PubMed ID: 15188142
[TBL] [Abstract][Full Text] [Related]
18. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase II beta: stability and distribution in different animal cells in comparison to DNA topoisomerase I and II alpha.
Negri C; Scovassi AI; Braghetti A; Guano F; Astaldi Ricotti GC
Exp Cell Res; 1993 May; 206(1):128-33. PubMed ID: 7683276
[TBL] [Abstract][Full Text] [Related]
20. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
